| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44733 | MSD SUB MERCK | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
Jan, 2026
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265009 | MSD SUB MERCK | HDP-CVD methodology for forming PMD layer |
Aug, 2020
(3 years ago) | |
| US7265099 | MSD SUB MERCK | Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
Aug, 2020
(3 years ago) | |
| US6949527 | MSD SUB MERCK | 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
Jan, 2021
(3 years ago) | |
Bridion is owned by Msd Sub Merck.
Bridion contains Sugammadex Sodium.
Bridion has a total of 4 drug patents out of which 3 drug patents have expired.
Expired drug patents of Bridion are:
- US7265009
- US7265099
- US6949527
Bridion was authorised for market use on 15 December, 2015.
Bridion is available in solution;intravenous dosage forms.
Bridion can be used as reversal of neuromuscular blockage induced by rocuronium bromide or vecuronium bromide, reversal of drug-induced neuromuscular block.
Drug patent challenges can be filed against Bridion from 16 December, 2019.
The generics of Bridion are possible to be released after 27 January, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 25, 2024 |
| M(M-291) | Jan 22, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2020 |
| M(M-262) | Jun 09, 2023 |
Drugs and Companies using SUGAMMADEX SODIUM ingredient
NCE-1 date: 16 December, 2019
Market Authorisation Date: 15 December, 2015
Treatment: Reversal of neuromuscular blockage induced by rocuronium bromide or vecuronium bromide; Reversal of drug-induced neuromuscular block
Dosage: SOLUTION;INTRAVENOUS
BRIDION family patents
